Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
In the latest session, GoodRx Holdings Inc (NASDAQ: GDRX) closed at $4.67 down -8.79% from its previous closing price of $5.12. In other words, the price has decreased by -$8.79 from its previous closing price. On the day, 13.64 million shares were traded. GDRX stock price reached its highest trading level at $5.25 during the session, while it also had its lowest trading level at $4.64.
Ratios:
For a deeper understanding of GoodRx Holdings Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.77 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8.56. For the most recent quarter (mrq), Quick Ratio is recorded 4.21 and its Current Ratio is at 4.21. In the meantime, Its Debt-to-Equity ratio is 0.85 whereas as Long-Term Debt/Eq ratio is at 0.84.
On December 04, 2024, Mizuho started tracking the stock assigning a Neutral rating and target price of $5.
Raymond James Upgraded its Outperform to Strong Buy on August 09, 2024, while the target price for the stock was maintained at $10.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 03 ’25 when Spectrum Equity VII, L.P. sold 10,677 shares for $4.80 per share. The transaction valued at 51,226 led to the insider holds 0 shares of the business.
Spectrum VII Investment Manage bought 6,828 shares of GDRX for $32,160 on Jul 03 ’25. On Jul 03 ’25, another insider, Spectrum VII Co-Investment Fun, who serves as the Affiliate of the company, bought 3,849 shares for $4.71 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GDRX now has a Market Capitalization of 1622591488 and an Enterprise Value of 2045164032. As of this moment, GoodRx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 50.32, and their Forward P/E ratio for the next fiscal year is 10.25. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.33. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.03 while its Price-to-Book (P/B) ratio in mrq is 2.56. Its current Enterprise Value per Revenue stands at 2.557 whereas that against EBITDA is 15.193.
Stock Price History:
The Beta on a monthly basis for GDRX is 1.25, which has changed by -0.37650198 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, GDRX has reached a high of $8.80, while it has fallen to a 52-week low of $3.31. The 50-Day Moving Average of the stock is 2.18%, while the 200-Day Moving Average is calculated to be 1.58%.
Shares Statistics:
For the past three months, GDRX has traded an average of 2.34M shares per day and 9122990 over the past ten days. A total of 99.90M shares are outstanding, with a floating share count of 81.18M. Insiders hold about 76.64% of the company’s shares, while institutions hold 15.76% stake in the company. Shares short for GDRX as of 1753920000 were 6367169 with a Short Ratio of 2.72, compared to 1751241600 on 5298433. Therefore, it implies a Short% of Shares Outstanding of 6367169 and a Short% of Float of 7.290000000000001.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 12.0 analysts currently analyzing and rating the stock of GoodRx Holdings Inc (GDRX).The consensus estimate for the next quarter is $0.1, with high estimates of $0.11 and low estimates of $0.08.
Analysts are recommending an EPS of between $0.4 and $0.34 for the fiscal current year, implying an average EPS of $0.38. EPS for the following year is $0.46, with 12.0 analysts recommending between $0.51 and $0.39.
Revenue Estimates
A total of 12 analysts believe the company’s revenue will be $195.17M this quarter.It ranges from a high estimate of $202.61M to a low estimate of $192.54M. As of the current estimate, GoodRx Holdings Inc’s year-ago sales were $195.25MFor the next quarter, 12 analysts are estimating revenue of $198.15M. There is a high estimate of $203.76M for the next quarter, whereas the lowest estimate is $194.1M.
A total of 14 analysts have provided revenue estimates for GDRX’s current fiscal year. The highest revenue estimate was $812.41M, while the lowest revenue estimate was $794.01M, resulting in an average revenue estimate of $798.73M. In the same quarter a year ago, actual revenue was $792.32MBased on 15 analysts’ estimates, the company’s revenue will be $841.9M in the next fiscal year. The high estimate is $871.41M and the low estimate is $816.1M.
